Focused On-demand Library for Pseudouridylate synthase 1 homolog

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q9Y606

UPID:
PUS1_HUMAN

ALTERNATIVE NAMES:
tRNA pseudouridine synthase 1; tRNA pseudouridine(38-40) synthase; tRNA pseudouridylate synthase I; tRNA-uridine isomerase I

ALTERNATIVE UPACC:
Q9Y606; A8K877; B3KQC1; Q8WYT2; Q9BU44

BACKGROUND:
The enzyme Pseudouridylate synthase 1 homolog, also referred to as tRNA-uridine isomerase I, is pivotal in the pseudouridylation process of tRNAs and mRNAs, acting on specific anticodon positions and mRNA sequences. Its regulatory function on pre-mRNA splicing and nuclear receptor activity through pseudouridylation of SRA1 mRNA underscores its significance in gene expression modulation.

THERAPEUTIC SIGNIFICANCE:
Given its association with the rare condition Myopathy with lactic acidosis and sideroblastic anemia 1, which manifests in progressive muscle weakness and anemia, the exploration of Pseudouridylate synthase 1 homolog's function offers promising avenues for therapeutic intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8296 of 8789